On October 1, 2025, Takeda Pharmaceutical, one of the world’s leading biopharmaceutical companies, officially unveiled a $170 million expansion of its facility in Thousand Oaks, California. The Japanese company, known globally for its commitment to developing innovative treatments, is doubling down on its mission to fight rare diseases, with a special focus on Hunter Syndrome,a devastating genetic disorder that affects only around 2,000 people worldwide.
This expansion not only strengthens Thousand Oaks’ reputation as a hub for biotechnology but also highlights Takeda’s unique approach in an industry often dominated by the pursuit of blockbuster drugs.
A Different Kind of Pharmaceutical Giant
Most big pharmaceutical companies focus on treatments for widespread conditions like cancer, diabetes, or cardiovascular disease, aiming for products that could reach millions of patients. Takeda, however, has built a strong reputation by prioritizing therapies for ultra-rare diseases.
Globally, Takeda employs about 50,000 people, with approximately 500 employees based in Thousand Oaks. Unlike others, Takeda’s mission goes beyond profit, it is rooted in personalized patient care.
At the ribbon-cutting event, Thomas Wozniewski, Takeda’s global manufacturing and supply officer, highlighted this commitment:
“We know our patients by name. Every vial has a name.”
This philosophy defines the company’s work, especially in treating conditions like Hunter Syndrome, where each patient’s life is profoundly impacted by the availability of effective therapies.
Hunter Syndrome: A Rare but Devastating Genetic Disorder
Hunter Syndrome, or Mucopolysaccharidosis II (MPS II), is a rare genetic condition that primarily affects boys. It can cause severe health challenges, including developmental delays, breathing problems, vision and hearing loss, seizures, heart disease, and shortened life expectancy. Most children diagnosed with the condition do not live past their 20s.
Among the patients benefiting from Takeda’s work is six-year-old Charlie McKay, who was diagnosed with Hunter Syndrome before birth. Charlie’s condition requires specialized treatments that help manage symptoms and improve quality of life.
Charlie’s mother, Kristin McKay, shared her family’s emotional journey during the expansion ceremony. She also serves as president and executive director of Project Alive, a nonprofit that advocates for families affected by Hunter Syndrome.
Kristin’s experience with the disease began when her younger brother, Zachary, was diagnosed with Hunter Syndrome as a child. At the time, there were virtually no treatments available. Tragically, Zachary passed away at the age of 19.
Years later, Kristin learned that her son Charlie had the same condition. But unlike her brother, Charlie now benefits from enzyme replacement therapy developed by Takeda.
Reflecting on the difference, she said:
“The life that kids get to live today with the treatments we have, it’s shocking. There’s been a lot of hope.”
Inside the $170 Million Expansion
The 15,000-square-foot expansion at Takeda’s Thousand Oaks facility represents years of planning and development. Construction began in 2021, and the completed project adds both new research space and advanced production capabilities for rare disease treatments. Highlights of the expansion include:
- Specialized laboratories and production areas dedicated to Hunter Syndrome therapy.
- A renovation of the existing facility to improve efficiency and capacity.
- A solar array that now generates about one-third of the property’s energy needs, reinforcing Takeda’s commitment to sustainability.
This investment underscores Takeda’s long-term dedication not only to patients but also to the Conejo Valley biotechnology ecosystem and the local workforce.
A Legacy of Biotechnology in Thousand Oaks
Takeda’s Thousand Oaks facility has a long history in biotechnology. Originally built in the 1990s by Baxter International, it became part of Baxalta, a Baxter spinoff, before Takeda acquired the site in 2019.
Today, the facility stands as the second-largest biotech employer in Thousand Oaks, after Amgen, which employs around 5,500 people locally. Takeda’s presence solidifies the city’s role as one of California’s most significant biotech hubs.
Community and Government Support
The unveiling of Takeda’s expansion attracted community leaders, company executives, and policymakers, all of whom praised the company’s commitment to California.
State Assemblymember Jacqui Irwin, representing Thousand Oaks, described Takeda as a vital contributor to the district’s innovation economy:
“While a lot of companies have decided to move manufacturing out of California or outside of the United States, you have committed to not only staying, but investing in a state-of-the-art facility here in Thousand Oaks. That speaks volumes to your confidence in our workforce and our economy.”
Her remarks underline the significance of Takeda’s decision to continue investing locally, especially at a time when some companies, including biotech leaders like Amgen, have shifted parts of their manufacturing outside the state.
A Competitive Biotechnology Landscape
Although some pharmaceutical giants have moved operations away from California due to costs, Thousand Oaks remains a center for biotech innovation. Takeda’s expansion is just one of several major investments in the area.
In September 2025, Amgen announced its own $600 million research and development center on its Thousand Oaks campus, located just a mile from Takeda’s facility. Together, these developments ensure that the city remains at the forefront of medical research, innovation, and life-changing therapies.
Beyond Medicine: A Human Impact
While the numbers, $170 million investment, 15,000 new square feet, 500 employees, highlight the scale of Takeda’s project, the real story lies in the lives it impacts. For families like the McKays, Takeda’s work means more than scientific progress; it means hope, better quality of life, and the possibility of longer futures for children like Charlie.
The company’s commitment to knowing every patient by name is not just a slogan but a guiding principle. With its latest expansion, Takeda is building on that promise, ensuring that rare disease patients are never forgotten in the broader pharmaceutical landscape.
Conclusion
The $170 million expansion of Takeda Pharmaceutical’s Thousand Oaks facility is more than just a business investment, it’s a commitment to science, patients, and the local community. By focusing on ultra-rare diseases like Hunter Syndrome, Takeda sets itself apart in an industry often driven by scale and profit.
For Thousand Oaks, this expansion means more jobs, more innovation, and a stronger biotech presence in California. For patients and families around the world, it means continued hope that life-saving treatments will not only improve quality of life but may one day lead to cures. As the Conejo Valley continues to grow as a global biotechnology hub, Takeda’s expansion stands as a symbol of what can be achieved when science, compassion, and innovation come together.
